This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
IRVINGTON, N.Y., April 18, 2013 (GLOBE NEWSWIRE) --
MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed
MelaFind®, today announced that it will be hosting a meeting for investors and analysts in conjunction with Melanoma Monday on May 6, 2013 from 10:00am to 11:00am Eastern time, in New York City.
Joseph V. Gulfo, MD, the Company's President and CEO, will host the meeting and will provide a brief introduction and business update. He will then moderate a panel discussion and presentations from leading dermatologists Mark S. Nestor, MD, PhD, Voluntary Associate Professor of the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine, and Dr. Gary Goldenberg, MD, Medical Director, Dermatology Faculty Practice at The Mount Sinai Medical Center, Assistant Professor of Dermatology and Pathology at the Mount Sinai School of Medicine. The clinicians will discuss their current practice patterns, the clinical utility of MelaFind and how they are incorporating it into their practice, as well as the product's potential market opportunity. Following the presentations, there will be a question and answer session.
A live audio webcast of the MELA Sciences Investor Meeting will be accessible through the investor relations section of Company's website at
www.melasciences.com. An archived edition of the presentation will be available later that day and will be available for at least 30 days afterward.
About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind
®, and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the U.S. Food and Drug Administration for use in the U.S. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.
For more information on MELA Sciences, visit
CONTACT: For Investors
Rpr Marketing Communications